ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

Core Insights - Esperion Therapeutics reported Q4 2025 EPS of 22 cents, missing the Zacks Consensus Estimate of 23 cents, while total revenues reached $168.4 million, a 144% year-over-year increase, surpassing the estimate of $161 million [1][7] Financial Performance - Total revenues for 2025 were $403.1 million, reflecting a 21% year-over-year growth, with a net loss of 11 cents per share for the year [10] - Product revenues from the U.S. in Q4 totaled $43.7 million, a 38% increase year-over-year, but fell short of the model estimate of $79 million [7] - Collaboration revenues surged 232% year-over-year to $124.7 million, driven by a one-time $90 million payment from Otsuka, exceeding both the Zacks Consensus Estimate and internal model estimates [7][8] Expenses - Research and development expenses increased by 26% year-over-year to $13.9 million due to higher costs in ongoing clinical studies [8] - Selling, general, and administrative expenses rose 12% year-over-year to $41.4 million, attributed to increased legal costs related to ANDA litigation [9] Recent Developments - Esperion announced the acquisition of Corstasis Therapeutics, expected to close in Q2 2026, which will add the Enbumyst nasal spray to its portfolio, targeting a market opportunity exceeding $4 billion in the U.S. [12][13][14] - A settlement agreement was reached with Alkem Laboratories and Dr. Reddy's regarding patents for Nexletol and Nexlizet, preventing the launch of generic versions before April 19, 2040, under certain conditions [15][16] Market Performance - Esperion's stock has increased by 77.6% over the past year, significantly outperforming the industry growth of 2.2% [4]